Text with patent numbers: |
|
||||||||||||||||||||||||
Title: | |||||||||||||||||||||||||
Abstract: | |||||||||||||||||||||||||
Specification: | |||||||||||||||||||||||||
Claims: | |||||||||||||||||||||||||
Inventor: | |||||||||||||||||||||||||
Assg. orig: | |||||||||||||||||||||||||
Assg. curr: | |||||||||||||||||||||||||
Expiry from: | to: | ||||||||||||||||||||||||
Priority from:sa | to: | ||||||||||||||||||||||||
Ref. by: | and more | Ind.cl: | and shorter | ||||||||||||||||||||||
Entity: | Type: | Expired: | Maint.status: | ||||||||||||||||||||||
Score from: | % to: % | Current assig. owns from to patents |
patent | score | priority | expiry | expired | references | current assignee | title |
---|---|---|---|---|---|---|---|
6307024 | 1 | 1999-03-09 | 2020-03-09 | 1 | 85 | ZYMOGENETICS, INC; | Cytokine zalpha11 Ligand |
6605272 | 1 | 1999-03-09 | 2020-03-09 | 1 | 63 | ZymoGenetics, Inc.; | Methods of using zalpha11 ligand |
6686178 | 1 | 1999-03-09 | 2020-03-09 | 1 | 51 | ZymoGenetics, Inc.; | Cytokine zalpha11 ligand polynucleotides |
8188234 | 1 | 2008-02-07 | 2029-04-07 | 0 | 85 | Merck Sharp & Dohme LLC; | 1D05 PCSK9 antagonists |
7473765 | 2 | 1999-03-09 | 2021-08-27 | 1 | 24 | ZymoGenetics, Inc.; | Cytokine zalpha11 ligand |
8188233 | 2 | 2008-02-07 | 2029-04-07 | 0 | 79 | Merck Sharp & Dohme LLC; | 1B20 PCSK9 antagonists |
6555654 | 7 | 1997-04-15 | 2018-04-15 | 1 | 6 | Merck Sharp & Dohme Corp; | LDL-receptor |
8344114 | 7 | 2006-11-07 | 2027-11-02 | 0 | 52 | Merck Sharp & Dohme LLC; | Antagonists of PCSK9 |
8110180 | 9 | 1999-03-09 | 2021-10-28 | 1 | 15 | ZymoGenetics, Inc.; | Method of use of cytokine ZALPHA11 ligand |
6545137 | 10 | 1997-04-15 | 2018-04-15 | 1 | 6 | Merck Sharp & Dohme Corp; | Receptor |
RE41129 | 13 | 1999-03-09 | 2020-03-09 | 1 | 6 | ZymoGenetics, Inc.; | Cytokine zalpha11 ligand polynucleotides |
7572892 | 17 | 1999-03-09 | 2020-09-16 | 1 | 6 | ZymoGenetics, Inc.; | Cytokine zalpha11 ligand fusion proteins |
7491800 | 18 | 1999-03-09 | 2021-04-01 | 1 | 7 | ZymoGenetics, Inc.; | Cytokine zalpha11 ligand fusion proteins |
7626002 | 23 | 1999-03-09 | 2020-11-20 | 1 | 1 | ZymoGenetics, Inc.; | Cytokine zalpha11 ligand antibodies |
7611699 | 27 | 1999-03-09 | 2020-09-15 | 1 | 5 | ZymoGenetics, Inc.; | Methods of using cytokine zalpha11 ligand |
8697070 | 27 | 2008-02-07 | 2029-02-06 | 1 | 13 | Merck Sharp & Dohme Corp.; | 1D05 PCSK9 antagonists |
7569670 | 43 | 1999-03-09 | 2020-11-16 | 1 | 2 | ZymoGenetics, Inc.; | Cytokine zalpha11 ligand fusion proteins |
8383775 | 49 | 1999-03-09 | 2020-03-09 | 1 | 1 | ZymoGenetics, Inc.; | Cytokine zalpha11 ligand |
8227575 | 54 | 1999-03-09 | 2020-03-09 | 1 | 0 | ZymoGenetics, Inc.; | Cytokine zalpha11 ligand antibodies |
8957194 | 59 | 2008-02-07 | 2029-02-06 | 1 | 2 | Merck Sharpe & Dohme Corp.; | 1B20 PCSK9 antagonists |
7829075 | 63 | 2006-02-02 | 2028-01-02 | 1 | 2 | ZymoGenetics, Inc.; | Method for expanding hematopoietic cells using cytokine zalpha11 ligand |
7579441 | 64 | 1999-03-09 | 2020-09-20 | 1 | 0 | ZymoGenetics, Inc.; | Cytokine zalpha11 ligand fusion proteins |
7592425 | 68 | 1999-03-09 | 2020-11-14 | 1 | 0 | ZymoGenetics, Inc.; | Cytokine zalpha11 ligand fusion proteins |
7998468 | 68 | 1999-03-09 | 2020-03-09 | 1 | 0 | ZymoGenetics, Inc.; | Cytokine zalpha11 ligand antibodies |
7244577 | 72 | 1997-04-15 | 2019-07-16 | 1 | 1 | Merck Sharp & Dohme Corp; | Method of screening for modulator of LRP5 activity |
8017343 | 76 | 1999-03-09 | 2020-03-17 | 1 | 0 | ZymoGenetics, Inc.; | Cytokine zalpha11 ligand antibodies and methods of use |